![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0002.jpg)
Page 12
Insights Nutr Metab 2017
Volume 1 Issue 1
September 15-16, 2017 | Dallas, USA
International Conference on
allied
academies
VITAMINS, NUTRIGENOMICS & MALNUTRITION
Notes:
M
etadichol (US patent 8,722,093 and 9043,383) is a
nanoemulsion of long-chain alcohols found in many
foods that are present in foods such as rice, sugar cane,
wheat, peanuts. Metadichol acts as inverse/Protean agonist
on Nuclear Vitamin D receptors (VDR) (US patent 9,006,292)
that are present in cells throughout the body to stimulate
the immune system. Metadichol® is first of a class of novel
nano-emulsion molecules which are a safe and effective
inhibitors of various biomarkers that affect many human
diseases especially in the area of endocrine disorders. Here,
in addition to acting on VDR, it shows cross reactivity against
other nuclear receptors and how this leads to mitigation of
infections including gene expression analysis and human
clinical case studies will be presented. Because it consists of
natural components of conventional foods and has no known
adverse side effects. Metadichol has the potential to serve as
a novel, vitamin D substitute for the widespread deficiency
that exists worldwide and overcome many chronic diseases.
Speaker Biography
P R Raghavan is the CEO of Nanorx Inc. He has a PhD in Organic Chemistry from Oregon
State University (1979) and an MS in Chemistry (1972) from IIT Mumbai, India. He
has worked on drug discovery for over 25 years at Columbia University, Max-Planck
Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over
15 US and international patents and another 15 pending patent applications.
e:
raghavan@nanorxinc.comP R Raghavan
Nanorx INC, USA
Metadichol®: A novel vitamin D receptor inverse/protean agonist and a vitamin D
substitute